A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3B STUDY TO EVALUATE THE SHORT- AND LONG-TERM EFFICACY AND SAFETY OF DUAL TARGETED THERAPY WITH INTRAVENOUS VEDOLIZUMAB AND ORAL UPADACITINIB COMPARED WITH INTRAVENOUS VEDOLIZUMAB MONOTHERAPY FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHN¿S DISEASE

Intervention/treatment:
VEDOLIZUMAB / UPADACITINIB
Medical condition:
CROHN'S DISEASE
Protocol code:
VEDOLIZUMAB-3043
Control number:
290824
Status:
Recruiting
Approved:
November 26, 2024
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06227910
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 65 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Takeda Contact
Role
CONTACT
Phone:
+1-877-825-3327
Sponsor
TAKEDA DEVELOPMENT CENTER AMERICAS INC

Locations

Alberta

Heritage Medical Research Clinic - University Of Calgary
Calgary, Alberta, T2N 4Z6
Active, not recruiting

Manitoba

University of Manitoba-Winnipeg Regional Health Authority-Health Sciences Centre
Winnipeg, Manitoba, R3A 1R9
Not yet recruiting
Name
Site Contact
Role
CONTACT
Phone:
2047872060
Name
Charles Bernstein
Role
PRINCIPAL_INVESTIGATOR

Nova Scotia

Dalhousie University
Halifax, Nova Scotia, B3H 2Y9
Not yet recruiting
Name
Site Contact
Role
CONTACT
Phone:
9024732612
Name
Michael Stewart
Role
PRINCIPAL_INVESTIGATOR

Ontario

Barrie GI Associates
Barrie, Ontario, L4M 7G1
Recruiting
Name
Site Contact
Role
CONTACT
Phone:
17057213344
Name
Rima Petroniene
Role
PRINCIPAL_INVESTIGATOR
McMaster University - Farncombe Family Digestive Health Research Institute (FFDHRI)
Hamilton, Ontario, L8S 4K1
Active, not recruiting
Taunton Surgical Centre-Oshawa Clinic
Oshawa, Ontario, L1J 0C7
Recruiting
Name
Site Contact
Role
CONTACT
Phone:
905-721-4964
Name
Daniel Green
Role
PRINCIPAL_INVESTIGATOR
Toronto Digestive Disease Associates
Vaughan, Ontario, L4L 4Y7
Not yet recruiting
Name
Site Contact
Role
CONTACT
Phone:
4166500017
Name
David Ford
Role
PRINCIPAL_INVESTIGATOR
Toronto Immune and Digestive Health Institute (TIDHI)
Toronto, Ontario, M6A 3B4
Recruiting
Name
Site Contact
Role
CONTACT
Phone:
6478122113
Name
Mark Silverberg
Role
PRINCIPAL_INVESTIGATOR

Quebec

Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2X 0A9
Not yet recruiting
Name
Site Contact
Role
CONTACT
Phone:
5142953671
Name
Robert Battat
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?

Contacts and resources